Overview
Sweden-based imaging solutions firm's Q4 net sales rose 42% yr/yr
Company's Q4 operating loss narrowed
Regulatory approvals in Europe and India expanded market reach
Outlook
SyntheticMR aims to reach profitability through sharper commercial execution and cost discipline
Company focuses on U.S. market growth and efficiency improvements
Demand for MRI follow-ups driven by new Alzheimer’s treatments presents growth prospects
Result Drivers
APAC GROWTH - Strong performance in APAC driven by OEM sales in Japan, deepening partnerships
REGULATORY APPROVALS - cMRI-ARIA and cMRI received regulatory approvals in Europe and India, expanding market reach
U.S. MARKET CHALLENGES - U.S. market underperformed due to difficulty in securing research grants, shifting focus to clinical sales
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
Beat
SEK 18 mln
SEK 13 mln (1 Analyst)
Q4 Net Income
-SEK 6 mln
Q4 Operating Profit
-SEK 5.30 mln
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."
Wall Street's median 12-month price target for SyntheticMR AB (publ) is SEK2.23, about 99% above its February 5 closing price of SEK1.12
Press Release:
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact .